Artiva Biotherapeutics (ARTV) Operating Expenses (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Operating Expenses for 4 consecutive years, with $24.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 10.19% year-over-year to $24.4 million; the TTM figure through Mar 2026 stood at $92.1 million (up 22.82% YoY), while the FY2025 annual figure was $89.8 million, up 32.99% from the prior year.
• Operating Expenses advanced to $24.4 million in Q1 2026 per ARTV's latest filing, from $21.9 million in the prior quarter.
• Across five years, Operating Expenses topped out at $24.4 million in Q1 2026 and bottomed at $14.3 million in Q4 2023.
• Historically, Operating Expenses has averaged $18.9 million across 4 years, with a median of $18.3 million in 2024.
• Annual changes were most pronounced in 2024 — Operating Expenses advanced 5.67% — and 2025, when it jumped 50.38%.
• Artiva Biotherapeutics' Operating Expenses stood at $14.3 million in 2023, then gained by 27.56% to $18.3 million in 2024, then advanced by 20.06% to $21.9 million in 2025, then gained by 11.39% to $24.4 million in 2026.
• Business Quant data shows ARTV's Operating Expenses at $24.4 million in Q1 2026, $21.9 million in Q4 2025, and $22.9 million in Q3 2025.